Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELDN NASDAQ:NAGE NASDAQ:TKNO NASDAQ:XBIT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$3.58+5.0%$3.56$1.35▼$4.60$263.21M0.94966,627 shs1.83 million shsNAGENiagen Bioscience$3.37-2.3%$4.23$3.35▼$14.69$274.77M2.08974,849 shs560,133 shsTKNOAlpha Teknova$4.65+2.0%$3.61$1.91▼$6.68$244.48M0.62153,561 shs120,621 shsXBITXBiotech$2.37$2.43$2.09▼$3.61$72.26M0.8529,048 shs23,171 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals0.00%-10.50%-12.11%+17.59%+10.71%NAGENiagen Bioscience0.00%-10.62%-17.27%-32.49%-73.36%TKNOAlpha Teknova0.00%-15.56%+19.06%+115.09%-23.10%XBITXBiotech0.00%-2.07%-3.66%+0.85%-18.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$3.58+5.0%$3.56$1.35▼$4.60$263.21M0.94966,627 shs1.83 million shsNAGENiagen Bioscience$3.37-2.3%$4.23$3.35▼$14.69$274.77M2.08974,849 shs560,133 shsTKNOAlpha Teknova$4.65+2.0%$3.61$1.91▼$6.68$244.48M0.62153,561 shs120,621 shsXBITXBiotech$2.37$2.43$2.09▼$3.61$72.26M0.8529,048 shs23,171 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals0.00%-10.50%-12.11%+17.59%+10.71%NAGENiagen Bioscience0.00%-10.62%-17.27%-32.49%-73.36%TKNOAlpha Teknova0.00%-15.56%+19.06%+115.09%-23.10%XBITXBiotech0.00%-2.07%-3.66%+0.85%-18.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals 2.40Hold$9.67170.02% UpsideNAGENiagen Bioscience 2.67Moderate Buy$10.50211.57% UpsideTKNOAlpha Teknova 2.33Hold$8.0072.04% UpsideXBITXBiotech 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest XBIT, ELDN, TKNO, and NAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026NAGENiagen Bioscience HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.005/8/2026XBITXBiotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/5/2026NAGENiagen Bioscience Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $10.004/24/2026XBITXBiotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026NAGENiagen Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)4/20/2026TKNOAlpha Teknova Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/31/2026NAGENiagen Bioscience Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.003/27/2026ELDNEledon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.35 per shareN/ANAGENiagen Bioscience$130.42M2.06$0.20 per share17.01$0.96 per share3.51TKNOAlpha Teknova$40.52M6.15N/AN/A$1.28 per share3.63XBITXBiotechN/AN/AN/AN/A$4.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$45.62M-$0.77N/AN/AN/AN/A-116.97%-41.91%8/13/2026 (Estimated)NAGENiagen Bioscience$17.38M$0.2116.0511.23N/A14.29%22.68%16.23%N/ATKNOAlpha Teknova-$17.26M-$0.32N/AN/AN/A-41.07%-24.32%-16.34%8/6/2026 (Estimated)XBITXBiotech-$45.54M-$1.32N/AN/AN/AN/A-26.10%-25.06%N/ALatest XBIT, ELDN, TKNO, and NAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026XBITXBiotech$0.03-$0.18-$0.21-$0.18$7.00 millionN/A5/13/2026Q1 2026ELDNEledon Pharmaceuticals-$0.22-$0.33-$0.11-$0.33N/AN/A5/6/2026Q1 2026NAGENiagen Bioscience$0.06$0.07+$0.01$0.07N/A$31.47 million5/6/2026Q1 2026TKNOAlpha Teknova-$0.0926-$0.08+$0.0126-$0.08$10.23 million$11.08 million3/19/2026Q4 2025ELDNEledon Pharmaceuticals-$0.20-$0.10+$0.10-$0.10N/AN/A3/13/2026Q4 2025XBITXBiotechN/A-$0.88N/A-$0.88N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/AXBITXBiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A8.448.44NAGENiagen BioscienceN/A4.613.55TKNOAlpha Teknova0.204.593.60XBITXBiotechN/A39.0339.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%NAGENiagen Bioscience15.41%TKNOAlpha Teknova13.81%XBITXBiotech55.70%Insider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals12.30%NAGENiagen Bioscience10.00%TKNOAlpha Teknova12.50%XBITXBiotech30.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1077.19 million67.69 millionOptionableNAGENiagen Bioscience12079.64 million71.68 millionN/ATKNOAlpha Teknova24053.61 million46.91 millionNot OptionableXBITXBiotech10030.49 million21.10 millionOptionableXBIT, ELDN, TKNO, and NAGE HeadlinesRecent News About These CompaniesXBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50 Day Moving Average - Time to Sell?May 30, 2026 | americanbankingnews.comXBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ RadarMay 14, 2026 | tipranks.comXBiotech: Q4 Earnings SnapshotMarch 13, 2026 | chron.comXBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?October 28, 2025 | msn.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insidersAugust 28, 2025 | finance.yahoo.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationMarch 2, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmMarch 1, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 28, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 27, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 26, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 25, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 24, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 23, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 22, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 21, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 20, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 18, 2025 | accessnewswire.comAXBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 17, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 16, 2025 | accessnewswire.comAXBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 15, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeXBIT, ELDN, TKNO, and NAGE Company DescriptionsEledon Pharmaceuticals NASDAQ:ELDN$3.58 +0.17 (+4.99%) Closing price 04:00 PM EasternExtended Trading$3.72 +0.15 (+4.05%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Niagen Bioscience NASDAQ:NAGE$3.37 -0.08 (-2.32%) Closing price 04:00 PM EasternExtended Trading$3.35 -0.02 (-0.68%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Alpha Teknova NASDAQ:TKNO$4.65 +0.09 (+1.97%) Closing price 04:00 PM EasternExtended Trading$4.63 -0.02 (-0.43%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.XBiotech NASDAQ:XBIT$2.37 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.38 +0.00 (+0.21%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Technology Stocks Just Got Cheaper—Here Are 5 Mega-Caps Worth a Closer Look Amprius Insiders Are Selling: Should Investors Be Worried? MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? Planet Labs: Coming Back Down to Earth Docusign: Another Beat, Another Selloff—Why the Analysts Are Wrong A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Nebius Is Up Nearly 175% This Year—Here's What's Driving the Latest Run Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
